Estrella Immunopharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ESLA research report →
Price Chart
About the company
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia.
- CEO
- Cheng Liu
- IPO
- 2021
- Employees
- 3
- HQ
- EmeryVille, CA, US
Get TickerSpark's AI analysis on ESLA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $18.30M
- P/E
- -1.74
- PEG
- -0.09
- P/S
- 0.00
- P/B
- -2.48
- EV/EBITDA
- -1.85
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 121.72%
- ROIC
- 131.75%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-13,062,674
- Net Income
- $-13,063,512-47.6%
- EPS
- $-0.35-45.8%
- OCF Growth
- +42.6%
- FCF Growth
- +42.6%
- 52W High
- $3.15
- 52W Low
- $0.41
- 50D MA
- $0.65
- 200D MA
- $1.07
- Beta
- 0.93
- RSI (14)
- 27
- Avg Volume
- 37.22K
No earnings-call transcripts are available for ESLA yet.
- Free Float
- 39.4%
- Shares Outstanding
- 43.50M
- Float Shares
- 16.81M
of shares held by institutions
16 13F filers
Buy/sell ratio 3.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Armistice Capital, LLC | 3.98M | ▼ 123.78K |
| Vanguard Group Inc | 448.76K | ▲ 29.05K |
| Vanguard Capital Management LLC | 416.85K | ▲ 34.38K |
| Geode Capital Management, LLC | 141.32K | ▼ 16.16K |
| Vanguard Fiduciary Trust Co | 64.92K | 0 |
| Blackrock, Inc. | 52.03K | ▲ 12.14K |
| State Street Corp | 43.25K | 0 |
| Atw Spac Management LLC | 40.00K | 0 |
| Renaissance Technologies LLC | 39.10K | ▼ 23.70K |
| Northern Trust Corp | 34.86K | ▲ 15.24K |
| Us Bancorp \De\ | 20.00K | ▲ 3.10K |
| Maso Capital Partners Ltd | 10.00K | 0 |
Held by 21 ETFs
Biggest fund positions in ESLA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 25, 26 | Liu Cheng | other | 100,000 |
| Aug 25, 26 | Liu Cheng | other | 100,000 |
| Aug 18, 26 | Xu Jiandong | other | 100,000 |
| Aug 18, 26 | Xu Jiandong | other | 100,000 |
| Oct 7, 25 | Xu Jiandong | buy | 1,000 |
| Sep 11, 25 | Xu Jiandong | buy | 100 |
| Sep 22, 25 | Xu Jiandong | buy | 1,000 |
| Sep 22, 25 | Jia Dengyao | other | 0 |
| Oct 30, 24 | Liu Cheng | other | 509,204 |
| Oct 30, 24 | Liu Cheng | other | 490,796 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ESLA coverage
Recent articles, reports, and earnings notes.
No research on ESLA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ESLA report →Estrella Immunopharma (NASDAQ:ESLA) Trading Up 1.1% – Should You Buy?
defenseworld.net · Aug 21
Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma
businesswire.com · Aug 11
Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma
businesswire.com · Aug 3
Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma
businesswire.com · Jul 29
Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin's Lymphoma
businesswire.com · Jul 24
Estrella Immunopharma to Participate in the D. Boral Capital Global Conference
businesswire.com · May 5
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research
businesswire.com · Mar 23
Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
businesswire.com · Feb 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.